Fasting lab markers to track: the biomarkers that tell you if it's working

Before beginning any fasting protocol beyond casual 12:12, run a baseline blood panel that includes: fasting glucose, fasting insulin, HbA1c, complete lipid panel (total cholesterol, LDL, HDL, triglycerides), C-reactive protein (CRP), complete metabolic panel (including sodium, potassium, magnesium, BUN, creatinine), and complete blood count. Optional additions: IGF-1 (if longevity is the goal), thyroid panel (TSH, free T3, free T4), and liver enzymes (ALT, AST). This panel costs $50 to $200 depending on insurance and lab choice.

Fasting glucose and fasting insulin together tell you more than either alone. Falling fasting glucose with falling fasting insulin indicates improving insulin sensitivity — the primary metabolic benefit of fasting. HbA1c reflects average blood sugar over the prior 2 to 3 months and is the gold standard for tracking glycemic control over time. Triglycerides are one of the most responsive lipid markers to fasting — a falling triglyceride level with a rising HDL is the classic metabolic improvement pattern. These four markers should be rechecked every 3 to 6 months during a sustained fasting practice.

C-reactive protein (CRP) is the most accessible inflammatory marker and responds to fasting within weeks. A falling CRP indicates reduced systemic inflammation, which is associated with reduced cardiovascular risk and improved metabolic health. If CRP is not moving despite consistent fasting, the inflammatory driver may be something other than metabolic — stress, sleep deprivation, chronic infection, or an autoimmune process. Additional inflammatory markers (IL-6, TNF-alpha, ferritin) are available but more expensive and less commonly needed for general fasting monitoring.

IGF-1 is the most commonly tracked longevity marker in fasting communities. Periodic fasting (particularly FMD cycles and extended water fasts) reduces IGF-1 levels, which is associated with reduced cancer risk in epidemiological studies. The target range is debated — too low increases frailty risk in older adults, too high may increase cancer risk. Most longevity-oriented physicians target the lower end of the reference range. Track IGF-1 every 6 to 12 months if longevity is the primary motivation.

During any fast beyond 48 hours, monitor: blood glucose (daily, by glucometer), blood pressure (daily), weight (daily), electrolytes (sodium, potassium, magnesium — at baseline and every 2 to 3 days during the fast), and kidney function (BUN, creatinine — at baseline and end of fast). Heart palpitations warrant an immediate electrolyte check. Dizziness warrants a blood pressure and glucose check. These are not optional during extended fasting — they are the monitoring that separates supervised fasting from dangerous experimentation.

Improving: fasting glucose falling, fasting insulin falling, HbA1c falling, triglycerides falling, HDL rising, CRP falling, blood pressure normalizing. Concerning: fasting glucose rising (possible cortisol-driven stress response), LDL rising significantly (possible lean-mass hypercholesterolemia), TSH rising (possible thyroid downregulation from caloric restriction), ALT or AST rising (possible liver stress). Any concerning change warrants a physician conversation and possible protocol adjustment. Not every metabolic change from fasting is beneficial, and biomarker tracking is how you distinguish the two.

For daily TRE protocols: retest the baseline panel at 3 months and 6 months. If markers are moving in the right direction, annual testing is sufficient. For periodic extended fasting or FMD: retest 2 to 4 weeks after each cycle. For therapeutic fasting (chronic disease management): follow the monitoring schedule set by your supervising physician. The cost of periodic blood work is modest compared to the value of knowing whether the protocol is working — and the cost of continuing a protocol that is not working is real.